Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Paula M Loria"'
Autor:
Nathanael G Lintner, Kim F McClure, Donna Petersen, Allyn T Londregan, David W Piotrowski, Liuqing Wei, Jun Xiao, Michael Bolt, Paula M Loria, Bruce Maguire, Kieran F Geoghegan, Austin Huang, Tim Rolph, Spiros Liras, Jennifer A Doudna, Robert G Dullea, Jamie H D Cate
Publikováno v:
PLoS Biology, Vol 16, Iss 4, p e1002628 (2018)
[This corrects the article DOI: 10.1371/journal.pbio.2001882.].
Externí odkaz:
https://doaj.org/article/3cb85e619abd466a91199f6643f6fcd9
Autor:
Nathanael G Lintner, Kim F McClure, Donna Petersen, Allyn T Londregan, David W Piotrowski, Liuqing Wei, Jun Xiao, Michael Bolt, Paula M Loria, Bruce Maguire, Kieran F Geoghegan, Austin Huang, Tim Rolph, Spiros Liras, Jennifer A Doudna, Robert G Dullea, Jamie H D Cate
Publikováno v:
PLoS Biology, Vol 15, Iss 3, p e2001882 (2017)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regulating the levels of plasma low-density lipoprotein cholesterol (LDL-C). Here, we demonstrate that the compound PF-06446846 inhibits translation of PCSK9 by inducing the ri
Externí odkaz:
https://doaj.org/article/c8c20b848f9a4b7e848edcb19074a5c8
Autor:
Thomas J. McCorvie, Paula M. Loria, Meihua Tu, Seungil Han, Leela Shrestha, D. Sean Froese, Igor M. Ferreira, Allison P. Berg, Wyatt W. Yue
Publikováno v:
Nature Structural & Molecular Biology. 29:628-638
Glycogen synthase (GYS1) is the central enzyme in muscle glycogen biosynthesis. GYS1 activity is inhibited by phosphorylation of its amino (N) and carboxyl (C) termini, which is relieved by allosteric activation of glucose-6-phosphate (Glc6P). We pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc44bb43ecd90e99ea2a1aab3f1fa3dc
https://doi.org/10.1038/s41594-022-00799-3
https://doi.org/10.1038/s41594-022-00799-3
Autor:
Allyn T. Londregan, Karlygash Aitmakhanova, James Bennett, Laura J. Byrnes, Daniel P. Canterbury, Xiayun Cheng, Thomas Christott, Jennifer Clemens, Steven B. Coffey, João M. Dias, Matthew S. Dowling, Gillian Farnie, Oleg Fedorov, Kimberly F. Fennell, Vicki Gamble, Carina Gileadi, Charline Giroud, Michael R. Harris, Brett D. Hollingshead, Kilian Huber, Magdalena Korczynska, Kimberly Lapham, Paula M. Loria, Arjun Narayanan, Dafydd R. Owen, Brigitt Raux, Parag V. Sahasrabudhe, Roger B. Ruggeri, Laura Díaz Sáez, Ingrid A. Stock, Benjamin A. Thuma, Andy Tsai, Alison E. Varghese
Publikováno v:
Journal of medicinal chemistry.
A series of small-molecule YEATS4 binders have been discovered as part of an ongoing research effort to generate high-quality probe molecules for emerging and/or challenging epigenetic targets. Analogues such as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f200505c5effa14e470509072c0e10b
https://pubmed.ncbi.nlm.nih.gov/36562986
https://pubmed.ncbi.nlm.nih.gov/36562986
Autor:
Kentaro Futatsugi, Shawn Cabral, Daniel W. Kung, Kim Huard, Esther Lee, Markus Boehm, Jonathan Bauman, Ronald W. Clark, Steven B. Coffey, Collin Crowley, Anne-Marie Dechert-Schmitt, Matthew S. Dowling, Robert Dullea, James R. Gosset, Amit S. Kalgutkar, Kou Kou, Qifang Li, Yajing Lian, Paula M. Loria, Allyn T. Londregan, Mark Niosi, Christine Orozco, John C. Pettersen, Jeffrey A. Pfefferkorn, Jana Polivkova, Trenton T. Ross, Raman Sharma, Ingrid A. Stock, Gregory Tesz, Hanna Wisniewska, Bryan Goodwin, David A. Price
Publikováno v:
Journal of medicinal chemistry. 65(22)
Discovery efforts leading to the identification of ervogastat (PF-06865571), a systemically acting diacylglycerol acyltransferase (DGAT2) inhibitor that has advanced into clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa977ae5e310187c2ba612493f2df69d
https://pubmed.ncbi.nlm.nih.gov/36322383
https://pubmed.ncbi.nlm.nih.gov/36322383
Autor:
David A. Griffith, David J. Edmonds, Jean-Philippe Fortin, Amit S. Kalgutkar, J. Brent Kuzmiski, Paula M. Loria, Aditi R. Saxena, Scott W. Bagley, Clare Buckeridge, John M. Curto, David R. Derksen, João M. Dias, Matthew C. Griffor, Seungil Han, V. Margaret Jackson, Margaret S. Landis, Daniel Lettiere, Chris Limberakis, Yuhang Liu, Alan M. Mathiowetz, Jayesh C. Patel, David W. Piotrowski, David A. Price, Roger B. Ruggeri, David A. Tess
Publikováno v:
Journal of medicinal chemistry. 65(12)
Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited because they require injection. Herein, we describe the discovery of the orally bioavailable, small-molecule, GLP-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff991134db369ff3aa7ceaecc2f6263e
https://pubmed.ncbi.nlm.nih.gov/35647711
https://pubmed.ncbi.nlm.nih.gov/35647711
Autor:
Kristin L. Rockwell, Paula M. Loria, Yue-Ming Wang, Marie-Claire Peakman, Andrea D. Weston, Claire M. Steppan, Regis Doyonnas, Fabien Vincent
Publikováno v:
Cell Chemical Biology. 27:1332-1346
The promise of phenotypic screening resides in its track record of novel biology and first-in-class therapies. However, challenges stemming from major differences between target-based and phenotypic screening do exist. These challenges prompted us to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4b71b25d5a4f6efc33dabb4992b5aad
https://doi.org/10.1016/j.chembiol.2020.08.009
https://doi.org/10.1016/j.chembiol.2020.08.009
Autor:
Jessica Ward, John Litchfield, Keith Riccardi, Carina Tan, Elnaz Menhaji-Klotz, Markus Boehm, Paula M. Loria, Kevin D. Hesp, Janice A. Brown
Publikováno v:
ACS Med Chem Lett
[Image: see text] The atypical chemokine receptor CXCR7 has been studied in various disease settings including immunological diseases and heart disease. Efforts to elucidate the role of CXCR7 have been limited by the lack of suitable chemical tools w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1e6eb2ef408c6d5c336c25957638d3f
https://doi.org/10.1021/acsmedchemlett.0c00163
https://doi.org/10.1021/acsmedchemlett.0c00163
Autor:
I. M. Ferreira, Wyatt W. Yue, D. S. Froese, L. Shrestha, T. J. McCorvie, M. Tu, Seungil Han, Paula M. Loria, A. P. Berg
Glycogen synthase (GYS1), in complex with glycogenin (GYG1), is the central enzyme of muscle glycogen biosynthesis, and its inhibition has been proposed as a therapeutic avenue for various glycogen storage diseases (GSDs). GYS1 activity is inhibited
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59da5a15b680c88b18b55d4f27839ec4
https://doi.org/10.1101/2021.11.12.468446
https://doi.org/10.1101/2021.11.12.468446
Autor:
Thomas J, McCorvie, Paula M, Loria, Meihua, Tu, Seungil, Han, Leela, Shrestha, D Sean, Froese, Igor M, Ferreira, Allison P, Berg, Wyatt W, Yue
Publikováno v:
Nature structuralmolecular biology. 29(7)
Glycogen synthase (GYS1) is the central enzyme in muscle glycogen biosynthesis. GYS1 activity is inhibited by phosphorylation of its amino (N) and carboxyl (C) termini, which is relieved by allosteric activation of glucose-6-phosphate (Glc6P). We pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fc38ae06ca98c14bed38dac24cc03833
https://pubmed.ncbi.nlm.nih.gov/35835870
https://pubmed.ncbi.nlm.nih.gov/35835870